logo
More states report illnesses, hospitalizations in salmonella outbreak linked to cucumbers

More states report illnesses, hospitalizations in salmonella outbreak linked to cucumbers

USA Today2 days ago

More states report illnesses, hospitalizations in salmonella outbreak linked to cucumbers The number of people sickened and hospitalized in a salmonella outbreak tied to tainted cucumbers continues to rise, health officials at the CDC and FDA say. Cases have now been reported in 18 states.
Show Caption
Hide Caption
Tips to help manage food recalls and prevent foodborne illnesses
About 128,000 are hospitalized and 3,000 people die each year from preventable foodborne illnesses.
Payton, USA TODAY
Salmonella illnesses linked to cucumbers continue to increase, with additional cases and hospitalizations reported in more states – and another major retailer, Target has issued its own recall.
The initial recall of cucumbers grown by Florida-based Bedner Growers and distributed by Fresh Start Produce Sales linked the produce to a salmonella outbreak across 15 states. The Food and Drug Administration and Centers for Disease Control and Prevention said on May 19 that 26 people had gotten ill and nine were hospitalized.
Health officials have now increased the number of illnesses reported to 45 in 18 states – Georgia, Indiana and Massachusetts are the latest states with cases – with hospitalizations due to salmonella poisoning up from nine to 16, according to the FDA and CDC.
Tough cookie: Oreo maker sues Aldi over alleged copycat cookie packaging
Eight people told health officials they had taken a cruise before becoming sick, according to the CDC. The passengers were aboard six different ships, all of which departed from Florida between March 30 and April 12 – three people were on the same ship, the agency said.
No deaths have been reported in the salmonella outbreak, the CDC says.
The initial voluntary recall involved cucumbers sold directly to consumers at Bednar's Farm Fresh Market. Subsequently, additional recalls have been announced by grocers such as Harris Teeter, Kroger and Walmart that repackaged whole cucumbers for sale or used them in ready-to-eat products such as vegetable trays and salads.
Target issued a recall for products purchased May 7 to May 21, the FDA said in its May 30 update. Those products included individual cucumbers, cucumber two-packs, and prepared foods such as Good & Gather Lemon Pepper Greek-Style Chicken Salad, Mai Spicy Salmon Rice Bowl with White Rice, and Mai California Roll with White Rice. The complete list of more than 40 recalled products with cucumbers is available on Target's product recall page.
Target was also among retailers recalling Hormel Foods' Dinty Moore Beef Stew because the product may contain fragments of "foreign material," specifically wood.
USA TODAY Recall Database: Search vehicle, product and food recalls
What to do if you think you may have recalled cucumbers
The recalled cucumbers should no longer be on store shelves, health officials said. The CDC and FDA advises anyone with cucumbers at home to throw them away if they're unsure where they're from. Wash any surfaces and items that may have touched the cucumbers.
Bedner Growers was also linked to a salmonella outbreak involving cucumbers last year that sickened 551 people and hospitalized 155 across 34 states and the District of Columbia, according to the CDC.
Investigators found untreated canal water carrying the bacteria used by Bedner Growers, the CDC said. While Bedner Growers and Thomas Produce Company of Boca Raton, Florida, were the likely sources of the outbreak, the CDC said, the companies did not account for all the outbreak's illnesses.
Salmonella symptoms
Each year, salmonella causes about 1.35 million illnesses, 26,500 hospitalizations, and 420 deaths in the U.S., according to the CDC and FDA.
Symptoms of salmonella infection – including diarrhea, fever and stomach cramps – usually arise six hours to six days after exposure and may last 4 to 7 days. Severe infections can also include aches, headaches, elevated fever, lethargy, rashes, and blood in the urine or stool.
Which states are affected by the salmonella outbreak?
As of May 30, the salmonella outbreak linked to cucumbers has sickened 45 people in the following 18 states:
Alabama
California
Colorado
Florida
Georgia
Illinois
Indiana
Kansas
Kentucky
Massachusetts
Michigan
North Carolina
New York
Ohio
Pennsylvania
South Carolina
Tennessee
Virginia
Contributing: Gabe Hauari and Mary Walrath-Holdridge.
Mike Snider is a reporter on USA TODAY's Trending team. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @mikegsnider.bsky.social & @mikesnider & msnider@usatoday.com
What's everyone talking about? Sign up for our trending newsletter to get the latest news of the day

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Business Upturn

timean hour ago

  • Business Upturn

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19
Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19

Business Insider

timean hour ago

  • Business Insider

Moderna announces FDA approved mNEXSPIKE, new vaccine against COVID-19

Moderna (MRNA) announced that the U.S. Food and Drug Administration, FDA, has approved mNEXSPIKE, a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,' said Stephane Bancel, Chief Executive Officer of Moderna. 'COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health.' Confident Investing Starts Here:

Tampa Bay Buccaneers $84 Million Defender Antoine Winfield Jr. Predicted for Rebound Season
Tampa Bay Buccaneers $84 Million Defender Antoine Winfield Jr. Predicted for Rebound Season

Yahoo

time2 hours ago

  • Yahoo

Tampa Bay Buccaneers $84 Million Defender Antoine Winfield Jr. Predicted for Rebound Season

Tampa Bay Buccaneers $84 Million Defender Antoine Winfield Jr. Predicted for Rebound Season originally appeared on Athlon Sports. Like much of the rest of the defense, Tampa Bay Buccaneers star safety Antoine Winfield Jr. had a less-than-stellar 2025. Advertisement The former Minnesota Golden Gopher dealt with an ankle injury for two separate parts of the season, causing him to miss eight total games in his first season after signing a four-year, $84.1 million deal with $45 million in guarantees to keep him in Tampa Bay. Winfield posted 60 total tackles with 34 solo and two for loss with four QB hits, two sacks and a 58-yard fumble recovery for a touchdown. While the Buccaneers have focused on improving one of the league's worst units from a year ago this offseason through free agency and the draft, a resurgent year from Winfield would go a long way toward the ultimate goal. Pro Football Focus named Winfield the Bucs' "bounce-back candidate" for next season. Advertisement 'Tampa Bay struggled to defend the middle of the field in 2024, due in part to injuries and a dip in production from star safety Antoine Winfield Jr", PFF said. "He posted a career-low 50.8 coverage grade and, for the first time in his career, failed to record an interception.' Winfield posted almost elite numbers in 2023, so we know the potential is there. And the ankle injury isn't expected to be a factor next season, so we could see his play return to that 2023 form. He'll turn 27 in August, so youth is still on his side. Tampa Bay is on an incredible run, tying a record four-straight NFC South titles, and has made the postseason five years running. Advertisement Related: Bucs Star Defender Reveals Hardest Offensive Coaches to Game Plan Against Related: Buccaneers Offensive Star Ranked Near Top of NFL This story was originally reported by Athlon Sports on Jun 1, 2025, where it first appeared.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store